Genprex, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

GNPX$2.06-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

	Common Stock
	Shares	Amount	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at December 31, 2023	29,735	$30	$141,104,634	$(133,688,280)	$7,416,384
Issuance of common stock, pre-funded warrants, and warrants, net of issuance costs	184,544	184	12,011,769	—	12,011,953
Issuance of common stock for services	1,028	1	206,984	—	206,985
Company issued rounding of fractional shares of street name accounts for reverse stock split	1,294	1	(1)	—	—
RSUs conversion to common stock	633	1	(2)	—	(1)
Share-based compensation	—	—	3,095,997	—	3,095,997
Deemed dividend related to warrant modification	—	—	(277,119)	—	(277,119)
Warrant modification	—	—	277,119	—	277,119
Net loss	—	—	—	(21,111,163)	(21,111,163)
Balance at December 31, 2024	217,234	$217	$156,419,381	$(154,799,443)	$1,620,155
Issuance of common stock, pre-funded warrants, and warrants, net of issuance costs	2,996,759	2,997	22,254,842	—	22,257,839
Issuance of common stock for services	400	—	7,948	—	7,948
Company issued rounding of fractional shares of street name accounts for reverse stock split	75,310	75	(75)	—	—
RSUs conversion to common stock	1,785	2	(2)	—	—
Share-based compensation	—	—	304,887	—	304,887
Net loss	—	—	—	(16,228,953)	(16,228,953)
Balance at December 31, 2025	3,291,488	$3,291	$178,986,981	$(171,028,396)	$7,961,876

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.